Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

摘要

The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, itshigh efficacy and favorable toxicityprofile led tonumerous studies evaluating BV inthe front-line, second-line, and posttransplant settings. BV is now approved for use (in combination with chemotherapy) as frontline treatment of advanced-stage patients and as maintenance therapy following autologous stem cell transplant. Additional studies demonstrateits promiseassecond-linetherapyand forelderlypatients, aswell.Although studieshave demonstratedits promise in multiple settings, the ideal timing for use of BV is evolving. Studies evaluating individualized treatment strategies will ultimately define the optimal place for BV in HL treatment.